Quick Answer
Benitec Biopharma Inc. reported Diluted EPS of $1.05 per share (loss) for fiscal year 2025.
Benitec Biopharma Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.05 | +13.9% |
| 2024 | -$1.22 | +91.4% |
| 2023 | -$14.12 | +62.7% |
| 2022 | -$37.88 | -1072.8% |
| 2021 | -$3.23 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.26 | +0.0% | -18.2% |
| September 30, 2025 | -$0.22 | -22.2% | +8.3% |
| March 31, 2025 | -$0.24 | -4.3% | +7.7% |
| December 31, 2024 | -$0.26 | +90.2% | -44.4% |
| September 30, 2024 | -$0.18 | +94.1% | +21.7% |
| March 31, 2024 | -$0.23 | +91.4% | +91.3% |
| December 31, 2023 | -$2.64 | +21.0% | +13.4% |
| September 30, 2023 | -$3.05 | +61.8% | -14.2% |
- Benitec Biopharma Inc. showed an increase of +13.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Benitec Biopharma Inc.’s diluted eps has grown by 67.5% (from $3.23 per share (loss) to $1.05 per share (loss)).
- The most recent figure is from Benitec Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: